Yahoo
NasdaqCM - Nasdaq Real Time Price USD

Viridian Therapeutics, Inc. (VRDN)

24.52 +0.59 (+2.47%)
As of 9:30:00 AM EDT. Market Open.
Trade VRDN on Coinbase
Chart Range Bar
Loading chart for VRDN
  • Previous Close 23.93
  • Open 24.50
  • Bid 17.00 x 200
  • Ask 29.45 x 200
  • Day's Range 24.49 - 24.52
  • 52 Week Range 13.18 - 34.29
  • Volume 33,879
  • Avg. Volume 2,038,337
  • Market Cap (intraday) 2.778B
  • Beta (5Y Monthly) 0.94
  • PE Ratio (TTM) --
  • EPS (TTM) -3.40
  • Earnings Date (est.) Nov 5, 2026
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est 36.62

Viridian Therapeutics, Inc. engages in discovering, developing, and commercializing treatments for serious and rare diseases. It develops IGF-1R therapies to treat thyroid eye disease (TED), including Veligrotrug, a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered, and Elegrobart, a low-volume, infrequently dosed subcutaneous IGF-1R. The company also develops an anti-thyroid-stimulating hormone receptor (TSHR) candidate for the treatment of Graves' disease and TED. Its portfolio of engineered inhibitors of the neonatal Fc receptor (FcFn) includes VRDN-006, a highly selective Fc fragment, and VRDN-008, a half-life extended bispecific FcRn inhibitor comprising an GC fragment and an albumin-binding domain designed to prolong IGG suppression. The company was formerly known as Miragen Therapeutics, Inc. and changed its name to Viridian Therapeutics, Inc. in January 2021. Viridian Therapeutics, Inc. was incorporated in 2010 and is headquartered in Waltham, Massachusetts.

www.viridiantherapeutics.com

252

Full Time Employees

December 31

Fiscal Year Ends

Healthcare

Sector

Biotechnology

Industry

Performance Overview

Trailing total returns as of 8/19/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .

YTD Return

VRDN
21.45%
S&P 500 (^GSPC)
12.87%

1-Year Return

VRDN
37.25%
S&P 500 (^GSPC)
20.51%

3-Year Return

VRDN
25.68%
S&P 500 (^GSPC)
76.81%

5-Year Return

VRDN
88.62%
S&P 500 (^GSPC)
75.37%

Earnings Trends

View More

Earnings Per Share

GAAP
Normalized
GAAP
Normalized

Revenue vs. Earnings

Annual
Quarterly
Annual
Quarterly
Q2 FY26
Revenue 284k
Earnings -127.12M

Q3

FY25

Q4

FY25

Q1

FY26

Q2

FY26

-100M
-50M
0
50M

Analyst Insights

View More

Analyst Price Targets

22.00
36.62 Average
24.52 Current
50.00 High

Analyst Recommendations

  • Strong Buy
  • Buy
  • Hold
  • Underperform
  • Sell

Latest Rating

Date 8/7/2026
Analyst RBC Capital
Rating Action Maintains
Rating Outperform
Price Action Raises
Price Target 35 -> 36

Statistics

View More

Valuation Measures

Annual
As of 8/17/2026
  • Market Cap

    2.71B

  • Enterprise Value

    2.07B

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    31.37

  • Price/Book (mrq)

    4.64

  • Enterprise Value/Revenue

    27.79

  • Enterprise Value/EBITDA

    --

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    0.00%

  • Return on Assets (ttm)

    -30.16%

  • Return on Equity (ttm)

    -65.74%

  • Revenue (ttm)

    71.13M

  • Net Income Avi to Common (ttm)

    -334.03M

  • Diluted EPS (ttm)

    -3.40

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    981.53M

  • Total Debt/Equity (mrq)

    36.96%

  • Levered Free Cash Flow (ttm)

    -275.5M

Compare

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Company Insights

Fair Value

24.52 Current

Dividend Score

0 Low
Sector Avg.
100 High

Hiring Score

0 Low
Sector Avg.
100 High

Insider Sentiment Score

0 Low
Sector Avg.
100 High

People Also Watch

Mobilize your Website
View Site in Mobile | Classic
Share by: